Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China
· Delayed Price · Currency is CNY 26.28
-0.56 (-2.09%)
At close: Mar 9, 2026
SHA:688443 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Operating Revenue | 230.72 | 30.07 | 1.07 | 0.48 | - | Upgrade
|
| Other Revenue | - | 0.03 | 0.15 | - | 39.19 | Upgrade
|
| Revenue | 230.72 | 30.09 | 1.21 | 0.48 | 39.19 | Upgrade
|
| Revenue Growth (YoY) | 666.65% | 2384.11% | 154.92% | -98.79% | 3502.99% | Upgrade
|
| Cost of Revenue | - | 5.92 | -0.24 | 1.77 | 19.67 | Upgrade
|
| Gross Profit | 230.72 | 24.17 | 1.45 | -1.3 | 19.52 | Upgrade
|
| Selling, General & Admin | - | 252.49 | 173.79 | 153.62 | 24.22 | Upgrade
|
| Research & Development | - | 609.79 | 620.4 | 454.49 | 295.32 | Upgrade
|
| Other Operating Expenses | 760.02 | 3.27 | 2.56 | 1.3 | 1.84 | Upgrade
|
| Operating Expenses | 760.02 | 866.19 | 796.74 | 609.42 | 321.34 | Upgrade
|
| Operating Income | -529.3 | -842.02 | -795.29 | -610.72 | -301.82 | Upgrade
|
| Interest Expense | - | -28.9 | -34.99 | -32.75 | -32.42 | Upgrade
|
| Interest & Investment Income | - | 66.75 | 17.46 | 0.88 | 0.43 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0.1 | -0.8 | 0.24 | Upgrade
|
| Other Non Operating Income (Expenses) | -6.92 | -0.02 | -0.02 | -0.01 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -536.22 | -804.18 | -812.94 | -643.39 | -333.59 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 2.58 | 1.94 | 7.14 | 4.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.54 | -0 | -0 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -0.43 | Upgrade
|
| Other Unusual Items | - | 4.86 | 9.68 | 59.89 | 7.78 | Upgrade
|
| Pretax Income | -536.22 | -797.27 | -801.32 | -576.37 | -322.13 | Upgrade
|
| Net Income | -536.22 | -797.27 | -801.32 | -576.37 | -322.13 | Upgrade
|
| Net Income to Common | -536.22 | -797.27 | -801.32 | -576.37 | -322.13 | Upgrade
|
| Shares Outstanding (Basic) | 365 | 367 | 321 | 274 | 275 | Upgrade
|
| Shares Outstanding (Diluted) | 365 | 367 | 321 | 274 | 275 | Upgrade
|
| Shares Change (YoY) | -0.72% | 14.63% | 16.79% | -0.32% | - | Upgrade
|
| EPS (Basic) | -1.47 | -2.17 | -2.50 | -2.10 | -1.17 | Upgrade
|
| EPS (Diluted) | -1.47 | -2.17 | -2.50 | -2.10 | -1.17 | Upgrade
|
| Free Cash Flow | - | -620.75 | -468.56 | -323.85 | -350.52 | Upgrade
|
| Free Cash Flow Per Share | - | -1.69 | -1.46 | -1.18 | -1.27 | Upgrade
|
| Gross Margin | 100.00% | 80.32% | 119.44% | -273.11% | 49.80% | Upgrade
|
| Operating Margin | -229.41% | -2797.87% | -65645.33% | -128506.77% | -770.14% | Upgrade
|
| Profit Margin | -232.41% | -2649.19% | -66142.68% | -121278.86% | -821.97% | Upgrade
|
| Free Cash Flow Margin | - | -2062.65% | -38675.98% | -68143.75% | -894.41% | Upgrade
|
| EBITDA | -474.18 | -786.89 | -746.46 | -570.86 | -270.57 | Upgrade
|
| EBITDA Margin | -205.52% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 55.12 | 55.12 | 48.84 | 39.86 | 31.26 | Upgrade
|
| EBIT | -529.3 | -842.02 | -795.29 | -610.72 | -301.82 | Upgrade
|
| EBIT Margin | -229.41% | - | - | - | - | Upgrade
|
| Revenue as Reported | - | 30.09 | 1.21 | 0.48 | 39.19 | Upgrade
|
| Advertising Expenses | - | 2.34 | 0.35 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.